Schütz W, Raberger G, Kraupp O
Arch Int Pharmacodyn Ther. 1978 Aug;234(2):214-20.
The glucagon-releasing activity of adenosine-5'-ethyl-carboxamide (744-96) was studied in conscious dogs pretreated either with aminophylline or with bupranolol, a beta-adrenoceptor blocking drug. The adenosine antagonist, aminophylline, inhibited both the glucagon-releasing and the blood pressure lowering effects of 744-96 (10 microgram/kg i.v.). The actions of the adenosine analogue on glucagon release and haemodynamics were not affected by bupranolol pretreatment. These results indicate that the adenosine analogue mediates glucagon release by interaction with so-called adenosine receptors. A beta-adrenoceptor mediated release secondary to 744-96-induced hypotension and baroreceptor-activation can be excluded.
在事先用氨茶碱或β-肾上腺素能受体阻断药布普洛尔预处理的清醒犬中,研究了5'-乙基-羧酰胺腺苷(744-96)的胰高血糖素释放活性。腺苷拮抗剂氨茶碱抑制了744-96(静脉注射10微克/千克)的胰高血糖素释放作用和降压作用。布普洛尔预处理不影响腺苷类似物对胰高血糖素释放和血流动力学的作用。这些结果表明,腺苷类似物通过与所谓的腺苷受体相互作用介导胰高血糖素释放。可以排除继发于744-96诱导的低血压和压力感受器激活的β-肾上腺素能受体介导的释放。